Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus nab-Paclitaxel in Recurrent/Metastatic Cervical Cancer
NCT05824494Phase 2Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Cervical Cancer (CC), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate up to 2 years. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05824494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824494.